感染治疗中的临床挑战：最新进展
Clinical challenges treating infections: an update.
作者信息
Mojica Maria F, Humphries Romney, Lipuma John J, Mathers Amy J, Rao Gauri G, Shelburne Samuel A, Fouts Derrick E, Van Duin David, Bonomo Robert A
机构信息
Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Case Western Reserve University-Cleveland VA Medical Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA.
出版信息
JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. eCollection 2022 Jun.
Abstract
is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of infections.
摘要
是一种非发酵革兰氏阴性杆菌，已成为一种机会性医院病原体。其固有的多重耐药性使得治疗由其引起的感染成为一项巨大的临床挑战。其分子异质性进一步使临床管理复杂化，这体现在不同菌株之间抗生素耐药性和毒力决定因素的分布不均、现有抗菌药物敏感性试验的缺点以及针对这种微生物有活性的少数几种抗生素缺乏标准化断点。在此，我们提供有关这些问题的最新文献综述，强调它们对感染临床管理的影响。
相似文献
1
Clinical challenges treating infections: an update.
JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. eCollection 2022 Jun.
2
Stenotrophomonas maltophilia: An emerging opportunistic nosocomial pathogen in a tertiary care hospital in Al Batinah North Governorate, Oman.
Sultan Qaboos Univ Med J. 2021 Feb;21(1):e66-e71. doi: 10.18295/squmj.2021.21.01.009. Epub 2021 Mar 15.
3
Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia.
Front Microbiol. 2015 Jun 30;6:658. doi: 10.3389/fmicb.2015.00658. eCollection 2015.
4
The Potential of Phage Therapy against the Emerging Opportunistic Pathogen .
Viruses. 2021 Jun 3;13(6):1057. doi: 10.3390/v13061057.
5
Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.
Ann Clin Microbiol Antimicrob. 2014 Dec 31;13:333. doi: 10.1186/s12941-014-0058-9.
6
Stenotrophomonas maltophilia drug resistance.
Future Microbiol. 2009 Aug;4(6):655-60. doi: 10.2217/fmb.09.45.
7
Antimicrobial therapy for Stenotrophomonas maltophilia infections.
Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):229-37. doi: 10.1007/s10096-007-0279-3.
8
Mechanisms of antimicrobial resistance in : a review of current knowledge.
Expert Rev Anti Infect Ther. 2020 Apr;18(4):335-347. doi: 10.1080/14787210.2020.1730178. Epub 2020 Feb 21.
9
Antimicrobial Peptide Exposure Selects for Resistant and Fit Stenotrophomonas maltophilia Mutants That Show Cross-Resistance to Antibiotics.
mSphere. 2020 Sep 30;5(5):e00717-20. doi: 10.1128/mSphere.00717-20.
10
Advances in the Microbiology of Stenotrophomonas maltophilia.
Clin Microbiol Rev. 2021 Jun 16;34(3):e0003019. doi: 10.1128/CMR.00030-19. Epub 2021 May 26.
引用本文的文献
1
Screening and comparison of -induced resistant and clinically resistant strains for eravacycline resistance-related genes.
Front Cell Infect Microbiol. 2025 Aug 15;15:1632701. doi: 10.3389/fcimb.2025.1632701. eCollection 2025.
2
Stenotrophomonas maltophilia complex: A broadly distributed emerging pathogen.
PLoS Pathog. 2025 Aug 21;21(8):e1013422. doi: 10.1371/journal.ppat.1013422. eCollection 2025 Aug.
3
Investigation and Management of a Small Outbreak of Septic Knee Arthritis Following Knee Arthroscopy by .
J Med Cases. 2025 Jul 8;16(7):239-247. doi: 10.14740/jmc5138. eCollection 2025 Jul.
4
First Report of from Canine Dermatological Infections: Unravelling Its Antimicrobial Resistance, Biofilm Formation, and Virulence Traits.
Antibiotics (Basel). 2025 Jun 23;14(7):639. doi: 10.3390/antibiotics14070639.
5
Mutation of Renders Resistant to First-Line Antibiotics Trimethoprim/Sulfamethoxazole and Levofloxacin.
Antibiotics (Basel). 2025 May 28;14(6):550. doi: 10.3390/antibiotics14060550.
6
Clinical metagenomics analysis of bacterial and fungal microbiota from sputum of patients suspected with tuberculosis infection based on nanopore sequencing.
Sci Rep. 2025 May 22;15(1):17772. doi: 10.1038/s41598-025-01905-3.
7
Evaluation of multidrug-resistant bacteria and their molecular mechanisms found in small animal veterinary practices in Portugal.
Front Cell Infect Microbiol. 2025 May 5;15:1582411. doi: 10.3389/fcimb.2025.1582411. eCollection 2025.
8
of clinical origin display higher temperature tolerance comparing with environmental isolates.
Virulence. 2025 Dec;16(1):2498669. doi: 10.1080/21505594.2025.2498669. Epub 2025 May 8.
9
Characterization of the novel cross-genus phage vB_SmaS_QH3 and evaluation of its antibacterial efficacy against .
Front Microbiol. 2025 Apr 11;16:1570665. doi: 10.3389/fmicb.2025.1570665. eCollection 2025.
10
Stenotrophomonas maltophilia endogenous endophthalmitis in an immunocompetent eye in Australia.
BMC Ophthalmol. 2025 Mar 28;25(1):158. doi: 10.1186/s12886-025-03990-4.
本文引用的文献
1
Evolution of cefiderocol resistance in using serial passage techniques.
JAC Antimicrob Resist. 2022 Feb 8;4(1):dlac011. doi: 10.1093/jacamr/dlac011. eCollection 2022 Mar.
2
Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.
Open Forum Infect Dis. 2022 Jan 17;9(2):ofab644. doi: 10.1093/ofid/ofab644. eCollection 2022 Feb.
3
Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Curr Drug Res Rev. 2022;14(1):20-23. doi: 10.2174/2589977513666211206100749.
4
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
5
Genome sequencing of the vermicompost strain Stenotrophomonas maltophilia UENF-4GII and population structure analysis of the S. maltophilia Sm3 genogroup.
Microbiol Res. 2021 Nov 18;255:126923. doi: 10.1016/j.micres.2021.126923.
6
Healthcare-Associated Stenotrophomonas maltophilia Bacteraemia: Retrospective Evaluation of Treatment and Outcome.
Cureus. 2021 Oct 20;13(10):e18916. doi: 10.7759/cureus.18916. eCollection 2021 Oct.
7
Colonization of the central venous catheter by Stenotrophomonas maltophilia in an ICU setting: An impending outbreak managed in time.
Am J Infect Control. 2022 Jun;50(6):663-667. doi: 10.1016/j.ajic.2021.10.026. Epub 2021 Nov 1.
8
Infections in Pediatric Patients - Experience at a European Center for Pediatric Hematology and Oncology.
Front Oncol. 2021 Oct 12;11:752037. doi: 10.3389/fonc.2021.752037. eCollection 2021.
9
Significance of When Detected in Sputum of Ambulatory Patients with COPD.
Int J Chron Obstruct Pulmon Dis. 2021 Oct 20;16:2895-2900. doi: 10.2147/COPD.S325419. eCollection 2021.
10
Antimicrobial Treatment Strategies for : A Focus on Novel Therapies.
Antibiotics (Basel). 2021 Oct 9;10(10):1226. doi: 10.3390/antibiotics10101226.
Zotero 插件